RJFSA
ACAD icon

Raymond James Financial Services Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-28,500
Closed -$1K – 2287
2016
Q1 		$1K Buy
+28,500
New +$621K ﹤0.01% 2075

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial Services Advisors's ACAD Position: Q2 2023 in Review

Raymond James Financial Services Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 14,670 shares — an estimated $276K sold.

Raymond James Financial Services Advisors first reported a position in ACAD in Q3 2015 and held it in 23 quarters. The position peaked at $2.15M in Q2 2016. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

  • Raymond James Financial Services Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 14,670 Acadia Pharmaceuticals shares in Q2 2023, an estimated $276K.
  • Raymond James Financial Services Advisors first reported a position in Acadia Pharmaceuticals in Q3 2015 and held it in 23 quarters.
  • Raymond James Financial Services Advisors's Acadia Pharmaceuticals position peaked at $2.15M in Q2 2016.
  • 236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.